Abstract
The steps that have led to the isolation, structural elucidation and chemical synthesis, and investigations into the biological properties of the arachidonic acid metabolites undoubtedly represent one of the most crucial developments in our understanding of the mechanisms that are intimately involved in inflammation.
Keywords
- Myocardial Infarct Size
- Human Lung Mast Cell
- Urinary LTE4
- Antileukotriene Drug
- Canine Myocardial Infarct
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kurzrok R, Lieb CC (1930) Biochemical studies of human semen. II. The action of semen on the human uterus. Proc Soc Exp Biol Med 28: 268–272
Feldberg W, Kellaway CH (1938) Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 94: 187–226
Brockelhurst WE (1960) The release of histamine and formation of a slow-reacting sub-stance (SRS-A) during anaphylactic shock. J Physiol 151: 416–435
Murphy RC, Hammarstrom S, Samuelsson B (1979) Leukotriene C: A slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 76: 4275–4279
Samuelsson B (1997) The discovery of the leukotrienes and the structure elucidation of SRA-A. In: S Holgate, SE Dahlen (eds): SRS-A to leukotrienes: The dawning of a new treatment. Blackwell Science, London, 39–49
Fitzimmons BJ, Rokach J (1989) The development of the new anti-leukotriene drugs: specific LTD4 antagonists and 5-LO inhibitors. In: J Rokach (ed): Leukotrienes and lipoxygenases. Elsevier, Amsterdam, 427–502
Batt DG (1992) 5-lipoxygenase inhibitors and their antiinflammatory activities. In: GP Ellis, DK Luscombe (eds): Progress in medicinal chemistry. Elsevier, Amsterdam, 1–63
O’Byrne PM, Israel E, Drazen J (1997) Antileukotrienes in the treatment of asthma. Ann Intern Med 127: 472–480
Spector SL (1997) Leukotriene activity modulation in asthma. Drugs 54 (3): 369–384
Brock TG, McNish RW, Peters-Golden M (1995) Translocation of leukotriene synthet-is capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. J Biol Chem 270: 21652–21658
Coleman RA, Smith WL, Narumiya S (1994) Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol Rev 46: 205–229
Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T (1997) A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387: 620–624
Nicosia S, Capra V, Accomazzo MR, Galbiati E, Ragnini D, Saponara R, Novarini S, Rovati E (1996) Receptors and second messengers for cys-leukotrienes. In: GC Folco, B Samuelsson, J Maclouf, GP Velo (eds): Eicosanoids: from biotechnology to therapeutic applications. Plenum Press, New York, 127–136
Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288: 484–486
Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of the 5lipoxygenase pathway — biochemistry and relation to pathobiology in human diseases. N Engl J Med 323: 645–655
Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M (1982) Slow-reacting substances, leukotriene C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 126: 449–451
Sautebin L, Viganò T, Grassi E, Crivellari MT, Galli G, Berti F, Mezzetti M, Folco GC (1985) Release of leukotrienes, induced by the Ca-ionophore A23187, from human lung parenchyma in vitro. J Pharmacol Exp Therap 243: 217–221
Weller PF, Lee CW, Foster D, Corey EJ, Austen KF (1983) Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci USA 80: 7626–7630
Peters SP, MacGlashan DW, Schulman ES, Schleimer RP, Hayes EC, Rokach J, Adkinson NF, Lichtenstein LM (1984) Arachidonic acid metabolism in purified human lung mast cells. J Immunol 132: 1972–1979
Miadonna A, Tedeschi A, Brasca C, Folco GC, Sala A, Murphy RC (1990) Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J Allergy Clin Immunol 85: 906–913
Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, Sala A, Vaghi A, Folco GC, Bianco S, Robuschi M (1996) Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 153: 572–575
Cloud ML, Enas GC, Kemp J (1989) A specific LTD4/LTE4 receptor antagonist improves pulmonary function in patients with mild chronic asthma. Am Rev Respir Dis 140: 1336–1339
Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453–460
Dreyling KW, Kozuschek W, Schaarschmidt K, Goebell H, Peskar BM (1987) Role of the endogenous leukotriene system in chronic inflammatory bowel disease. Prog Clin Biol Res 242: 309–315
Bonnet C, Bertin P, cook-Moreau J, Chable-Rabinovitch H, Treves R, Rigaud M (1995) Lipoxygenase products and expression of 5-lipoxygenase and FLAP in human cultured synovial cells. Prostaglandins 50 (3): 127–135
Griffiths RG, Pettipher ER, Koch K, Farrell CA, Breslow R, Conklyn MJ, Smith MA, Hackman BC, Wimberly DJ, Milici AJ (1995) Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 92 (2): 517–521
Lauritsen K, Laursen LS, Burhavc K, Rask-Madsen J (1986) Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91: 837–844
Letts LG (1987) Leukotrienes: role in cardiovascular physiology. Cardiovascular Clinics 18 (1): 101–113
Lefer AM (1988) Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders. Prog Clin Biol Res 264: 101–114
Vigorito C, Giordano A, Cirillo R, Genovese A, Rengo F, Marone G (1997) Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man. Int J Clin Lab Res 27 (3): 178–184
Marone G, deCrescenzo G, Adt M, Patella V, Arbustini E, Genovese A (1995) Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31 (1): 1–18
Carry M, Korley V, Willerson JT, Weigelt JT, Ford-Hutchinson AW, Tagari P (1992) Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85: 230–236
Scoggan KA, Jakobsson PJ, Ford-Hutchinson AW (1997) Production of leukotriene C4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J Biol Chem 272 (15): 10182–10187
Hashimoto H, Miyazawa K, Hagiwara M, Miyasaka K, Nakashima M (1990) Beneficial effects of a new 5-lipoxygenase inhibitor on occlusion and occlusion-reperfusioninduced myocardial injury. Arzneim Forsch Drug Res 40: 126–129
Sasaki K, Ueno A, Kawamura M, Katori M, Shigehiro S, Kikawada R (1987) Reduction of myocardial infarct size in rats bby a selective 5-LO inhibitor (AA-861). Adv Prostaglandin Thromboxane Leukot Res 17: 381–383
Amsterdam EA, Pan HL, Rendig SV, Symons JD, Fletcher MP, Longhurst JC (1993) Limitation of myocardial infarct size in pigs with a dual lipoxygenase-cyclooxygenase blocking agent by inhibition of neutrophil activity without reduction of neutrophil migration. J Am Coll Cardiol 22: 1738–1744
Toki Y, Hieda N, Torii T, Hashimoto H, Ito T, Ogawa K, Satake T (1988) The effect of lipoxygcnase inhibitor and peptidoleukotriene antagonist on myocardial injury in a canine coronary occlusion-reperfusion model. Prostaglandins 35(4): 555–571
Mullane K, Hatala MA, Kraemer R, Sessa W, Westlin W (1987) Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J Cardiovasc Pharmacol 10 (4): 398–406
Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Müller-Peddinghaus R, Maclouf J, Folco GC (1996) Myocardial protection by the leukotriene synthesis inhibitor BAY X 1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Therap 276: 335–341
Hahn RA, MacDonald BR, Simpson PJ, Wang L, Towner RD, Ho PP, Goodwin M, Breau AP, Suarez T, Mihelic ED (1991) Characterization of LY233569 on 5-LO and reperfusion injury of ischemic myocardium. J Pharmacol Exp Ther 256 (1): 94–102
Hock CE, Beck LD, Papa LA (1992) Peptide leukotriene receptor antagonism in myocardial ischemia and reperfusion. Cardiovascular Res 26 (12): 1206–1211
Ito BR, Roth DM, Engler RL (1990) Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circulation Res 66 (3): 596–607
Ito T, Toki Y, Hieda N, Okumura K, Hashimoto H, Ogawa K, Satake T (1989) Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn Circ J 53 (9): 1115–1121
Hahn RA, MacDonald BR, Morgan E, Potts BD, Parli CJ, Rinkema LE, Whitesitt CA, Marshall WS (1992) Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury. J Pharmacol Exper Ther 260: 979–989
Hahn RA, MacDonald BR, Simpson PJ, Potts BD, Parli CJ (1990) Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. J Pharmacol Exper Ther 253: 58–66
Egan JW, Griswold DE, Hillegass LM, Newton JF, Eckardt RD, Slivjak MJ, Smith EF (1989) Selective antagonism of peptidoleukotriene responses does not reduce myocardial damage or neutrophil accumulation following coronary artery occlusion with reperfusion. Prostaglandins 37 (5): 597–613
Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH (1993) Enhanced excretion of urinary LTE4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 4 (10): 899–904
Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, Hanauer SB, Reagan JE, Cagliola A, Tanaka WK et al (1997) Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 112: 725–732
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this chapter
Cite this chapter
Folco, G. (1999). Inhibitors of leukotrienes: An overview. In: Folco, G., Samuelsson, B., Murphy, R.C. (eds) Novel Inhibitors of Leukotrienes. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8703-8_14
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8703-8_14
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9736-5
Online ISBN: 978-3-0348-8703-8
eBook Packages: Springer Book Archive